The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways

Mariateresa Mancuso, Simona Leonardi, Paola Giardullo, Emanuela Pasquali, Fabiana Borra, Ilaria De Stefano, Maria Grazia Prisco, Mirella Tanori, Giovanni Scambia, Vincenzo Di Majo, Simonetta Pazzaglia, Anna Saran, Daniela Gallo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Gender-related differences in medulloblastoma (MB) development have been reported with a higher incidence in males (slightly above 60%) than in females, female gender being also a significantly favorable prognostic factor in MB. The present study focused on the evaluation of the mechanisms by which estrogens protect against MB formation. To this end, we used a well characterized mouse model of MB - the Patched1 heterozygous mice. Ovariectomized mice were treated with 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), a highly potent ERβ agonist, or 4,4',4″-(4-propyl-[1. H]-pyrazole-1,3,5-triyl) trisphenol (PPT), a highly potent ERα agonist. Our results show that the ERβ selective agonist DPN significantly inhibits development of MB preneoplastic lesions when compared with untreated ovariectomized mice, restoring the final incidence to that observed in the intact controls, and that these effects were achieved via activation of anti-proliferative and pro-apototic pathways. On the other hand, the ERα selective agonist PPT did not influence MB tumorigenesis relative to untreated ovariectomized mice. © 2011 Elsevier Ireland Ltd.
Original languageEnglish
Pages (from-to)197 - 202
Number of pages6
JournalCancer Letters
Volume308
Issue number2
DOIs
Publication statusPublished - 28 Sep 2011
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this